

# Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases (AVITHRAPID)

---

Prof. Dr. Björn Windshügel

## Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

- The scientific and clinical communities have an **increased knowledge on viruses with epidemic potential** and in particular a better understanding of different potential mechanisms of action for the development of broad-spectrum anti-viral therapeutics for these viruses.
- The scientific and clinical communities have **access to novel approaches for the development of anti-viral therapies for emerging and re-emerging infections** in the context of epidemic and pandemic preparedness.
- The scientific and clinical communities have **access to experimental broad-spectrum anti-viral candidates against emerging or re-emerging viral infections** for further clinical investigation.
- **A diverse and robust pipeline of broad-spectrum anti-viral drug candidates** is available for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.

1

### **Supporting pandemic preparedness by provision of novel approaches for development of antivirals**

- Identification and validation of novel targets for broad-spectrum antivirals

2

### **Development of novel broad-spectrum antivirals for current and future epidemics and pandemics**

- Lead development of promising hit series towards pre-clinical candidates with high potency and beneficial safety profile
- Development of innovative targeting and delivery systems for addressing challenging infections
- Clinical trial of a compound against infections with Zika virus

3

### **Setup of a R&D pipeline for rapid development of antiviral compounds against emerging diseases**

- Supporting the development of future antiviral substances

# AVITHRAPID

## Consortium Composition

---

### Italy

- Università degli Studi della Tuscia
- Università degli Studi di Siena
- Elettra Sincrotrone Trieste Scpa
- University of Naples Federico II
- INMI Spallanzani
- Università degli Studi di Cagliari
- Università degli Studi di Roma "Tor Vergata"
- Dompé farmaceutici SpA
- Euresist Network GEIE

### Switzerland

- Chelonia SA
- Swiss Tropical and Public Health Institute

### Netherlands

- First Health Pharmaceuticals B.V.

### Germany

- Fraunhofer-Gesellschaft zur Foerderung der Angewandten Forschung e.V.

### Latvia

- Latvian Institute of Organic Synthesis

AVITHRAPID  
PROJECT

### Czech Republic

- VSB – Technical University of Ostrava


### Portugal

- Gulbenkian Institute for Molecular Medicine

### France

- Université de Tours
- Institut national de recherche pour l'agriculture, l'alimentation et l'environnement


EXSCALATE  
4COV



# AVITHRAPID

## Pipeline

AVITHRAPID  
PROJECT



Existing compounds with potent bioactivity against several targets identified by AVITHRAPID consortium partners



**European  
Lead Factory**

<https://avithrapid.eu>